Skip to content
AnalystLens

Idex Annual Report, Year Ended Dec 31, 2012

Filing Date
Filed February 21, 2013
Period End
December 31, 2012
Security
IEX
One revenue dollarkept$0.02
In the record · 2016–202610-K1110-Q338-K119

IEX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.

  1. FY2016 annual report10-K · Feb ’17Feb ’17
  2. Material agreement8-K · Jun ’19Jun ’19
  3. Leadership change8-K · Feb ’22Feb ’22
  4. Leadership change8-K · Dec ’25Dec ’25

Summary

Summary of the 10-K filed February 21, 2013. Cited figures are marked; the original filing is the authoritative source.

IDEX Corporation's 2012 Form 10-K reports net sales of $1,954,258 thousanda, up 6% from $1,838,451 thousand in 2011, with organic sales up 3%.

Operating income fell 58% to $128,218 thousandb, driven by a $198,519 thousand asset impairment charge recorded in the fourth quarter, largely tied to the IOP (Optics & Photonics) and WST (Water Services & Technology) platforms. Net income decreased 81% to $37,630 thousand, and diluted EPS was $0.45 versus $2.32 in 2011. The effective tax rate rose to 56.3%, mainly due to the nonrecurring impairment charge, which the filing says increased the rate by 26.9%.

By segment, Fluid & Metering Technologies generated 43% of 2012 sales and 82% of operating income, Health & Science Technologies contributed 35% of sales with a negative operating income of $(62,835) thousand, and Fire & Safety/Diversified Products provided 22% of sales and 53% of operating income. Cash flow from operations rose to $326,180 thousandc, and cash and cash equivalents were $318,864 thousand at year end. Total borrowings were $786,576 thousand, and the company stated it was in compliance with its financial covenants, with an interest coverage ratio of 10.05 to 1 and a leverage ratio of 1.92 to 1.

For 2013, management forecast fully diluted EPS of $2.85 to $2.95d. The company repurchased 2.2 million shares for $89.6 million during 2012, and the board increased the repurchase authorization by $200.0 million in October 2012.

Key Highlights

  1. Net sales of $1.95 billion rose 6%, with organic sales up 3% and acquisitions contributing 5%.
  2. Operating income fell 58% to $128.2 million, reflecting a $198.5 million non-cash asset impairment charge in Q4 2012.
  3. Diluted EPS was $0.45, down $1.87 or 81% from $2.32 in 2011; the effective tax rate rose to 56.3%.
  4. Health & Science Technologies posted an operating loss of $62.8 million due to $170.8 million of impairment charges.
  5. Cash flow from operating activities increased 50% to $326.2 million, and cash and equivalents totaled $318.9 million.
  6. Management forecasts 2013 fully diluted EPS of $2.85 to $2.95.
  7. Total borrowings were $786.6 million, with covenant compliance at an interest coverage ratio of 10.05 to 1 and a leverage ratio of 1.92 to 1.

Follow one dollar

Of each $1.00 of revenue in FY2012, Idex kept $0.02.

  1. Revenue$1.95B100.0%
  2. Cost of revenue−$1.15B58.9%
  3. Gross profit$803.7M41.1%
  4. Operating costs−$675.5M34.6%
  5. Operating income$128.2M6.6%
  6. Interest, other & tax−$90.6M4.6%
  7. Net income$37.6M1.9%
Computed from 10-KFY2012filed February 21, 2013Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Where FY2012 revenue went

$1.95B
  • Cost of revenue: $1.15B, 59% of revenue
  • SG&A: $444.5M, 23% of revenue
  • Net income: $37.6M, 1.9% of revenue
  • R&D: $36.4M, 1.9% of revenue
  • Other operating costs: $194.6M, 10.0% of revenue
  • Interest, other & tax: $90.6M, 4.6% of revenue

Kept 1.9% as net incomeNet income $37.6M · 1.9%R&D $36.4M · 1.9%

Full revenue history →

Financial Statements

FY2012 against FY2011

Line itemFY2012FY2011Change
Revenue$1.95B$1.84B+6.3%
Cost of Revenue$1.15B$1.10B+4.6%
Gross Profit$803.70M$738.67M+8.8%
R&D Expenses$36.40M$36.00M+1.1%
SG&A Expenses$444.49M$421.70M+5.4%
Operating Income$128.22M$304.66M−57.9%
Interest Expense$42.25M$29.33M+44.0%
Net Income$37.63M$193.86M−80.6%
EPS (Basic)$0.45$2.34−80.8%
EPS (Diluted)$0.45$2.32−80.6%
Shares Outstanding (Basic)82.69M82.14M+0.7%
Shares Outstanding (Diluted)83.64M83.54M+0.1%

Frequently Asked Questions

  1. What caused the sharp decline in 2012 operating income?

    The decline was primarily due to $198.5 million of asset impairment charges, mainly within the IOP reporting unit (CVI Melles Griot, Optics & Photonics) and the WST reporting unit (municipal water). Restructuring charges also rose to $32.5 million from $12.3 million.

  2. What is the company's 2013 earnings outlook?

    Based on its current outlook, the company forecast fully diluted EPS of $2.85 to $2.95 for 2013.

  3. How strong is the company's balance sheet and debt position?

    At December 31, 2012, total borrowings were $786.6 million against shareholders' equity of $1.46 billion. Cash and equivalents were $318.9 million, and $672.5 million of the $700.0 million Revolving Facility was net available. The company stated it was in compliance with its financial covenants.

  4. How is the company returning capital to shareholders?

    IDEX declared cash dividends of $0.80 per share in 2012, up from $0.68 in 2011. It repurchased 2.2 million shares for $89.6 million during 2012, and in October 2012 the board increased the repurchase authorization by $200.0 million, leaving $235.4 million available at year end.

  5. How geographically diversified are the company's sales?

    In 2012, approximately 51% of total sales were to customers outside the U.S. Net sales were $963.1 million in the U.S., $479.7 million in Europe and $511.4 million in other countries.